BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024. In the quarter to June 2026, revenue grew 29.6%, EPS grew 143.7%, free cash flow grew 117.9% and total debt rose 503.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

369.06 5.02 −1.34%
Market cap
$39.0B
P/E
62.6×
Fwd P/E
40.2×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

587.41 116.40 63.86 48.30
P/S ratio
7.55 6.20 5.74 5.19
P/FCF ratio
71.58 35.95 30.10 24.27
P/Operating CF
93.28 79.39 163.66 68.70
P/B ratio
9.09 7.60 6.92 6.15
EV/Sales
6.83 5.59 5.13 4.55
EV/EBITDA
100.35 50.74 35.23 25.89
EV/FCF
64.78 32.41 26.91 21.30
Current Ratio
2.39 3.41 3.64 3.41
Net Debt/EBITDA
(19.45) (16.22) (13.16) (11.53)
Debt/Equity
0.03 0.22 0.20 0.17
Earnings Yield
0.17% 0.86% 1.57% 2.07%
Free Cash Flow Yield
1.40% 2.78% 3.32% 4.12%
Free Cash Flow per Share
3.22 3.48 1.45 3.90
Book value per Share
37.47 39.99 42.90 46.37
Free Cash Flow
354.47 379.83 160.55 435.34
EV/EBIT
186.02 66.82 42.94 30.23
Other line items

Show all line items

Columns are period end dates